Literature DB >> 31770191

Non-coding RNA and lung cancer progression.

Afeez Adekunle Ishola1,2, Anita Silas La'ah1,2, Hung Dinh Le2, Viet Quoc Nguyen2, Yi-Ping Yang1,3, Shih-Jie Chou1, Hsiao-Yun Tai1, Chian-Shiu Chien1, Mong-Lien Wang1,4,5.   

Abstract

Lung cancer (LC) is a major killer disease globally. This situation is further supported by yearly increase in new LC cases and its poor 5-year survival which is less than 15%. Although a large percentage of LC cases have been attributed to smoking, a considerable amount of nonsmokers also develops this disease, thereby suggesting a genetic and/or epigenetic undertone to LC development. Several growth-related genes such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) as well as tumor suppressor genes such as p53 have been implicated in LC pathogenesis and progression. Likewise, the genome only contains approximately 1% of coding regions. Hence, noncoding portion of the genome such as noncoding RNAs (ncRNAs) has been studied and discovered to play a cogent role in LC pathogenesis. More precisely, microRNAs (miRNAs) and long ncRNAs (lncRNAs) have been studied for decades. Posttranscriptional gene modulation function of miRNAs is well established and characterized. Likewise, the antagonizing interaction between lncRNAs and miRNAs had also been proven to further control gene expression during healthy and disease conditions like LC. More recently, renewed attention toward circular RNAs [circular RNAs (circRNAs)] study showed that circRNAs can also sponge miRNAs to modulate gene expressions too. Hence, miRNAs, lncRNAs, and circRNAs seem to function within a circuit to optimally determine which gene is needed to be upregulated or downregulated in biological system. Therefore, this review will discuss important ncRNAs, namely miRNA, lncRNA, and circRNA in LC progression. Paracrine effect of exosomal ncRNA will be also reviewed. In addition, the prospect of these ncRNAs in enhancing better LC treatment will be highlighted as well.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31770191     DOI: 10.1097/JCMA.0000000000000225

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  8 in total

1.  Identification and Validation of Long Non-Coding RNA LCIIAR as a Biomarker in LUAD.

Authors:  Wenjun Ren; Yixiao Yuan; Xi Chen; Haoqing Zhai; Yin An; Lin Tang; Juan Wang; Dahang Zhang; Liren Zhang; Wanli Cheng; Xin Wang; Lincan Duan; Luciano Mutti; Bin Han; Ping Wang
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

2.  Identification of Competing Endogenous RNA and Micro-RNA Profiles and Regulatory Networks in 4-Nonylphenol-induced Impairment of Sertoli Cells.

Authors:  Wenjie Liu; Zhaokai Wang; Xiaopeng Hu
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

Review 3.  RNA-based therapies: A cog in the wheel of lung cancer defense.

Authors:  Parvez Khan; Jawed Akhtar Siddiqui; Imayavaramban Lakshmanan; Apar Kishor Ganti; Ravi Salgia; Maneesh Jain; Surinder Kumar Batra; Mohd Wasim Nasser
Journal:  Mol Cancer       Date:  2021-03-19       Impact factor: 27.401

4.  LncRNA CCDC26 Interacts with CELF2 Protein to Enhance Myeloid Leukemia Cell Proliferation and Invasion via the circRNA_ANKIB1/miR-195-5p/PRR11 Axis.

Authors:  Chengliang Li; Jianjun Mu; Yingpeng Shi; Hong Xin
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

5.  Downregulation of lncRNA FGF12-AS2 suppresses the tumorigenesis of NSCLC via sponging miR-188-3p.

Authors:  Lili Zhou; Chen Xing; Dongxia Zhou; Rong Yang; Maohuai Cai
Journal:  Open Med (Wars)       Date:  2020-10-08

Review 6.  Circular RNAs Modulate Cancer Hallmark and Molecular Pathways to Support Cancer Progression and Metastasis.

Authors:  Aliaksandr A Yarmishyn; Afeez Adekunle Ishola; Chieh-Yu Chen; Nalini Devi Verusingam; Vimalan Rengganaten; Habeebat Aderonke Mustapha; Hao-Kai Chuang; Yuan-Chi Teng; Van Long Phung; Po-Kuei Hsu; Wen-Chang Lin; Hsin-I Ma; Shih-Hwa Chiou; Mong-Lien Wang
Journal:  Cancers (Basel)       Date:  2022-02-09       Impact factor: 6.639

7.  miR-31-3p functions as a tumor suppressor by directly targeting GABBR2 in prostate cancer.

Authors:  Sujin Choi; Soonchul Lee; Young-Hoon Han; Junwon Choi; Isaac Kim; Jusung Lee; Hyun-Ju An
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

8.  LncRNA NEAT1 Acts as an miR-148b-3p Sponge to Regulate ROCK1 Inhibition of Retinoblastoma Growth.

Authors:  Hang Lu; Zhenjun Zhang; Yao Lu; Weiwei Xiu; Jinglin Cui
Journal:  Cancer Manag Res       Date:  2021-07-12       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.